Jiangsu Canopus Wisdom Medical Technology Co.,Ltd. (SHE:301290)
China · Delayed Price · Currency is CNY 22.62
-0.60 (-2.58%)
At close: Jul 22, 2026
SHE:301290 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 393.01 | 380.72 | 430.47 | 430.5 | 440.73 | 442.57 |
Other Revenue | 6.77 | 6.77 | 4.99 | 3.23 | 1.37 | 3.93 |
| 399.78 | 387.49 | 435.46 | 433.73 | 442.1 | 446.5 | |
Revenue Growth (YoY) | -5.23% | -11.02% | 0.40% | -1.89% | -0.98% | 19.25% |
Cost of Revenue | 203.66 | 202.1 | 221.08 | 225.86 | 210.6 | 195.33 |
Gross Profit | 196.11 | 185.39 | 214.38 | 207.88 | 231.5 | 251.17 |
Selling, General & Admin | 111.82 | 110.17 | 112.72 | 106.62 | 93.08 | 104.58 |
Research & Development | 21.38 | 20.97 | 22.43 | 27.11 | 24.21 | 20.67 |
Other Operating Expenses | 4.87 | 4.59 | 5.18 | 2.65 | 4.39 | 3.14 |
Operating Expenses | 138.93 | 134.99 | 140.77 | 135.94 | 124.56 | 128.17 |
Operating Income | 57.18 | 50.39 | 73.6 | 71.94 | 106.94 | 123 |
Interest Expense | -1.51 | -1.27 | -0.34 | -0.06 | -0.13 | -0.11 |
Interest & Investment Income | 25.85 | 25.8 | 39.4 | 16.25 | 5.28 | 2.4 |
Currency Exchange Gain (Loss) | -0.51 | -0.51 | -0.14 | -0.02 | 0.49 | -0.1 |
Other Non Operating Income (Expenses) | -0.25 | -0.14 | -0.1 | -0.05 | -0.28 | -0.34 |
EBT Excluding Unusual Items | 80.77 | 74.26 | 112.42 | 88.05 | 112.3 | 124.85 |
Impairment of Goodwill | -99.72 | -99.72 | - | - | - | - |
Gain (Loss) on Sale of Investments | 3.69 | 3.01 | -7 | 13.69 | 0.5 | - |
Gain (Loss) on Sale of Assets | -0.04 | -0.04 | -0.09 | -0.59 | -0.43 | -0.25 |
Asset Writedown | -5.65 | -5.63 | - | - | - | - |
Other Unusual Items | 0.35 | 0.54 | 9.73 | 15.91 | 7.44 | 5.33 |
Pretax Income | -20.59 | -27.58 | 115.06 | 117.06 | 119.82 | 129.93 |
Income Tax Expense | 13.46 | 12.32 | 18.17 | 17.18 | 16.1 | 18.86 |
Earnings From Continuing Operations | -34.05 | -39.9 | 96.89 | 99.88 | 103.72 | 111.07 |
Minority Interest in Earnings | 1.96 | 1.96 | 0.53 | -2.66 | -1.21 | -0.82 |
Net Income | -32.09 | -37.94 | 97.42 | 97.22 | 102.51 | 110.25 |
Net Income to Common | -32.09 | -37.94 | 97.42 | 97.22 | 102.51 | 110.25 |
Net Income Growth | - | - | 0.21% | -5.15% | -7.03% | 38.33% |
Shares Outstanding (Basic) | 100 | 100 | 99 | 100 | 77 | 75 |
Shares Outstanding (Diluted) | 100 | 100 | 99 | 100 | 77 | 75 |
Shares Change (YoY) | -0.09% | 0.43% | -0.81% | 30.05% | 2.76% | 10.45% |
EPS (Basic) | -0.32 | -0.38 | 0.98 | 0.97 | 1.33 | 1.47 |
EPS (Diluted) | -0.32 | -0.38 | 0.98 | 0.97 | 1.33 | 1.47 |
EPS Growth | - | - | 1.03% | -27.07% | -9.52% | 25.64% |
Free Cash Flow | 43.23 | 38.03 | 10.54 | 51.68 | 20.28 | 67.78 |
Free Cash Flow Per Share | 0.43 | 0.38 | 0.11 | 0.52 | 0.26 | 0.90 |
Dividend Per Share | 0.300 | 0.300 | 0.600 | 0.600 | 0.500 | - |
Dividend Growth | -50.00% | -50.00% | - | 20.00% | - | - |
Gross Margin | 49.05% | 47.84% | 49.23% | 47.93% | 52.36% | 56.25% |
Operating Margin | 14.30% | 13.00% | 16.90% | 16.59% | 24.19% | 27.55% |
Profit Margin | -8.03% | -9.79% | 22.37% | 22.41% | 23.19% | 24.69% |
Free Cash Flow Margin | 10.81% | 9.81% | 2.42% | 11.91% | 4.59% | 15.18% |
EBITDA | 98.05 | 91.52 | 115.76 | 109.58 | 141.18 | 150.64 |
EBITDA Margin | 24.53% | 23.62% | 26.58% | 25.26% | 31.93% | 33.74% |
D&A For EBITDA | 40.86 | 41.12 | 42.15 | 37.64 | 34.24 | 27.64 |
EBIT | 57.18 | 50.39 | 73.6 | 71.94 | 106.94 | 123 |
EBIT Margin | 14.30% | 13.00% | 16.90% | 16.59% | 24.19% | 27.55% |
Effective Tax Rate | - | - | 15.79% | 14.68% | 13.44% | 14.52% |
Revenue as Reported | 399.78 | 387.49 | 435.46 | 433.73 | 442.1 | 446.5 |
Advertising Expenses | - | 1.64 | 2.07 | 1.87 | 1.34 | 2.48 |